SC
CYTK icon

SummitTX Capital’s Cytokinetics CYTK Stock Holding History

SummitTX Capital’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.62M Buy
112,893
+63,182
+127% +$4.54M 0.25% 93
2026
Q1 		$3.28M Buy
+49,711
New +$3.16M 0.1% 225
2025
Q2 		– Sell
-13,357
Closed -$537K – 799
2025
Q1 		$537K Buy
+13,357
New +$614K 0.02% 532

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SummitTX Capital's CYTK Position: Q2 2026 in Review

SummitTX Capital increased its Cytokinetics (CYTK) stake by 127% in Q2 2026, buying an estimated $4.54M and bringing the position to 112,893 shares worth $9.62M. The position accounts for 0.25% of the portfolio, ranked #93.

SummitTX Capital first reported a position in CYTK in Q1 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • SummitTX Capital held 112,893 shares of Cytokinetics worth $9.62M as of Q2 2026.
  • SummitTX Capital bought 63,182 Cytokinetics shares in Q2 2026, an estimated $4.54M.
  • Cytokinetics made up 0.25% of SummitTX Capital's portfolio in Q2 2026, its #93 holding.
  • SummitTX Capital first reported a position in Cytokinetics in Q1 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.